Objective-The beneficial effect of the natural compound propionyl-L-carnitine (PLC) on intermittent claudication in patients with peripheral arterial disease is attributed to its anaplerotic function in ischemic tissues, but inadequate information is available concerning action on the vasculature. Methods and Results-We investigated the effects of PLC in rabbit hind limb collateral vessels after femoral artery excision, mouse dorsal air pouch, chicken chorioallantoic membrane, and vascular cells by angiographic, Doppler flow, and histomorphometrical and biomolecular analyses. PLC injection accelerated hind limb blood flow recovery after 4 days (PϽ0.05) and increased angiographic quadriceps collateral vascularization after 7 days (PϽ0.001) Histomorphometry confirmed the increased vascular area (PϽ0.05), with unchanged intramuscular capillary density. PLCinduced dilatative adaptation, and growth was found associated with increased inducible nitric oxide synthase and reduced arterial vascular endothelial growth factor and intracellular adhesion molecule-1 expression. PLC also increased vascularization in air pouch and chorioallantoic membrane (PϽ0.05), particularly in large vessels. PLC increased endothelial and human umbilical vascular endothelial cell proliferation and rapidly reduced inducible nitric oxide synthase and NADPH-oxidase 4 -mediated reactive oxygen species production in human umbilical vascular endothelial cells; NADPH-oxidase 4 also regulated NF-B-independent intracellular adhesion molecule-1 expression. Conclusion-Our results provided strong evidence that PLC improves postischemic flow recovery and revascularization and reduces endothelial NADPH-oxidase-related superoxide production. We recommend that PLC should be included among therapeutic interventions that target endothelial function. (Arterioscler Thromb Vasc Biol. 2010;30:426-435.)
P eripheral arterial disease (PAD) is the most common clinical consequence of atherosclerosis, affecting Ϸ20% of adults older than age 55 years. 1 Atherosclerotic occlusion of leg arteries induces clinical manifestations, most frequently intermittent claudication. 1, 2 Among the functional vascular changes observed with atherosclerosis, endothelial dysfunction plays a major role. 3, 4 L-carnitine is a natural amino acid that plays a crucial role in the shuttle mechanism of long-chain fatty acids and in fueling ␤ oxidation. 5 The endogenous L-carnitine pool includes a series of short-chain, medium-chain, and long-chain esters in homeostatic equilibrium. 5, 6 Propionyl-L-carnitine (PLC) is a short-chain L-carnitine ester that has been introduced among emerging noninterventional medical regiments that aim to counteract PAD-related adverse effects. 1, 2, 7 PLC activity is classically related to the anaplerotic function of providing substrates for energy expenditure in ischemic tissues. 1, 8 Although some data showed beneficial remodeling after injury, 9 the mechanisms through which PLC influences arterial function remain largely hypothetical. Recently, oxidative stress was implicated in PLCinduced flow-mediated dilatation in PAD patients. 10 Arterial occlusion leads to 2 distinct adaptive mechanisms, namely angiogenesis via capillary sprouting 11 and arteriogenesis via dilatation and growth of preexisting collateral vessels. 12, 13 Arteriogenesis provides much more blood flow than angiogenesis and represents a crucial step in vascular function maintenance and tissue reperfusion after vascular occlusion. 12, 13 The latter induces an immediate shear-stress increase in collateral vessels that undergo an early adaptive dilatation, which is subsequently followed by growth through proliferation of arterial cells and extracellular matrix accumulation. 12, 13 To better understand the vascular machinery, we investigated PLC effects in various models and in vascular cell cultures, with specific reference to the modulation of oxidative stress-induced endothelial dysfunction.
Materials and Methods
A detailed methods description is available in the Supplemental Materials (available online at http://atvb.ahajournals.org).
Rabbit Hind Limb Ischemia
All animal procedures conformed to the Principles of Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals (1996) . Unilateral hind limb ischemia 14 was performed by left femoral artery excision in New Zealand rabbits (Charles River-Italy Spa). After 3 days, PLC (Sigma-Tau SpA; Pomezia) was injected in 1 mL saline into 3 points of the quadriceps muscle. Contralateral vehicle injection was the nonischemic control.
Arteriogenesis and Tissue Perfusion Assessment
A blinded morphometric analysis of the hind limb collateral vessels was performed by angiography after a contrast medium injection through the internal iliac artery. Before the angiography, the laser Doppler flowmetry measurement was reported as ischemicto-normal limb blood flow ratio. 15
Morphometric Determination of Rabbit Hind Limb Vascular Area and Capillary Density
Serial quadriceps muscle sections were stained with hematoxylin and eosin and Verhoeff-Van Gieson. Vascular and vessel areas were calculated according to morphometric criteria. 9 Intramuscular capillary density per mm 2 and intramuscular capillary density normalized to muscle fiber diameter were measured on biotinylated isolectinstained sections.
Air Pouch Assay
The vascular area and the number of vessels were calculated after 7 days in the mouse dorsal cervix sac by subcutaneously injecting 3 mL air. Then, an intrapouch administration of 500 L of saline alone or with 25 or 50 mg/mouse PLC was performed.
Chicken Chorioallantoic Membrane Vasculogenesis Assay
We applied 2 L of a 390 mmol/L PLC solution, L-carnitine, or sodium propionate (Sigma-Tau) to a chicken chorioallantoic membrane surface using a gelatin sponge. Fibroblast growth factor-2 (50 ng/embryo) and phosphate-buffered saline were used as positive and negative controls, respectively. The increase (⌬ vessels) of capillaries converging toward the implant was counted under a stereomicroscope 72 hours after the implant. Evaluation of the number of ␣-smooth muscle actin-positive (␣-actin) vessels was also performed. 9
Immunohistochemistry
After antigen retrieval, immunohistochemistry 9 was performed by incubating sections with anti-vascular endothelial growth factor, anti-inducible nitric oxide synthase (iNOS), anti-NF-Bp65 (Santa Cruz Biotechnology), anti-NOS (BD Biosciences), anti-vascular cell adhesion molecule-1, anti-intracellular adhesion molecule-1 (Novus Biologicals), anti-␣-actin, anti-RAM11, and anti-Ki67 (DakoCytomation) using positive and negative controls. The percentages of positive vessels and staining intensity 16 were calculated according to morphometric criteria.
Cell Culture
Second passage human umbilical vein endothelial cells (HUVEC; Cambrex) were starved for 24 hours and then incubated with 2% fetal bovine serum or 0.1% fetal bovine serum and PLC dissolved in phosphate-buffered saline or phorbol 12-myristate 13-acetate (10 nmol/L). Smooth muscle cells (SMC) were obtained from the inner portion of rabbit femoral artery. 9 After starvation, SMC were cultured in the presence of 10% or 0.1% fetal bovine serum and PLC at various concentrations. [ 3 H]thymidine incorporation, apoptosis, and cell viability were also determined. 17 Results were expressed as the mean of 3 different experiments.
Adhesion Assay
Confluent HUVEC were treated with PLC at a 1 mmol/L concentration for 24 hours. Monocytes were separated by Ficoll-Paque and incubated with HUVEC for 1 hour at 37°C. Nonadherent cells were removed during 3 gentle washing steps. Adhering cells were fixed in 2% paraformaldehyde and counted in triplicate.
Protein Extraction and Western Blot Analysis
The total protein extracts from multiple quadriceps muscle biopsies or from cultured cells was quantified by Bradford assay. Aliquots were separated by gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted to nitrocellulose transfer membranes, incubated with specific antibodies, and quantified by densitometric analysis in 3 independent experiments. 17
Rac1 Activity Assay
Rac1 activity was determined by a commercially available kit (Upstate Biotechnology) according to manufacture's guidelines.
Reverse-Transcriptase and Real-Time Polymerase Chain Reaction
RNA was extracted from cells, quadriceps muscle biopsies, and chorioallantoic membranes; 17 semiquantitative reverse-transcriptase polymerase chain reaction was performed in triplicate. Primer sequences are available in the Supplemental Materials. Results were normalized on the hypoxanthine-guanine phospho-ribosyltransferase or glyceraldehyde-3phosphate dehydrogenase expression. NADPH oxidase subunits, Rac-1, and intracellular adhesion molecule-1 (ICAM-1) expression was analyzed by real-time polymerase chain reaction 17 and normalized on glyceraldehyde-3-phosphate dehydrogenase level. The copy number of nox isoforms mRNA was also calculated.
Electrophoretic Mobility Shift Assay
Nuclear extracts from 2ϫ10 6 cells were prepared for the electrophoretic mobility shift assay. 17 Protein concentrations were determined and electrophoretic mobility shift assay and supershift assays were performed using an NF-B-specific oligonucleotide (Invitrogen).
Detection of Reactive Oxygen Species
The intracellular reactive oxygen species (ROS) level in HUVEC was measured by 5-(and-6)-chloromethyl-2Ј,7Ј-dichlorodihydrofluorescein diacetate acetyl ester fluorescence method (Molecular Probes). Fluorescence was monitored by analyzing at least 10 000 cells in a flow cytometer.
Interfering RNA for NADPH Oxidases
Small interfering RNA (siRNA) for human Nox2 (access NM 000397) and Nox4 (access NM 016931) were designed by using Block-IT RNAi Designer (Invitrogen). The siRNA and scramble sequences are available in the Supplemental Materials. Nox isoform depletion by siRNA was confirmed by reverse-transcription polymerase chain reaction and blot.
Statistical Analysis
Data were expressed as the meanϮSEM, and differences were analyzed by a Student t test and 1-way ANOVA or ANCOVA followed by Dennett test. Blinded measurements were performed by 2 independent researchers; the interobserver reproducibility was Ͼ95%. Differences were considered statistically significant at a value of PϽ0.05.
Results

PLC Accelerates Revascularization and Ameliorates Postischemic Blood Flow Recovery in Rabbit Hind Limb
Seven days after PLC injection, iliac arteriography ( Figure  1A , B) documented a beneficial effect compared to controls (PϽ0.001) that was still present, although smaller, after 2 weeks. The PLC effect was dose-dependent up to 10 mg and did not further increase at 20 mg ( Figure 1C ), with an EC 50 value of 5.86 mg/kg Three days after femoral artery resection (basal value; Figure 1D ), blood flow reduction was Ϸ70%. PLC induced faster flow recovery compared to saline ischemic controls (EC 50 at 7 days, 1.561 mg/kg) and was already significant 4 days after injection (PϽ0.05; Supplemental  Table I , available online at http://atvb.ahajournals.org).
PLC Increases Hind Limb Vascular Area but Not Intramuscular Capillary Angiogenesis
To better-analyze the effects of PLC, we investigated rabbit quadriceps collateral vessels at a 10-mg dose by histomorphometrical analysis. Seven days after PLC injection ( Figure  2A ), a consistent increase in vascular area compared to saline control (PϽ0.05) was observed, with a 6-fold increase of the lumen area. Intramuscular capillary density and capillary-tomuscle fiber ratio did not vary ( Figure 2B , C).
PLC Improves Arteriogenesis of Rabbit Quadriceps Collateral Vessels
We also investigated arteriogenesis 12 7 days after PLC injection. Endothelial cell swelling and Ki-67-positive cells were detected in collateral vessels ( Figure 2D ), as reported. 12 Contralateral nonischemic vessels were almost Ki-67-negative (not shown). An eccentric intimal thickening from variable rounded SMC accumulation was detected in ischemic collateral vessels. The percentage of vessels showing subendothelial focal intimal SMC accumulation was reduced in PLC compared to saline ischemic controls (PϽ0.01; Figure 2E ). Also, Ki-67-positive endothelial cells were increased in PLC-treated rabbits compared to saline ischemic controls (PϽ0.05; Figure 2F ). The opposite was observed for intimal SMC (PϽ0.05). Immunostaining also revealed that PLC-induced arteriogenetic remodeling occurs with no significant change in ␣-actin-positive collateral vessel number (not shown).
PLC Increases Vascularization in Mouse Air Pouch and Chicken Chorioallantoic Membrane
We investigated PLC effects in vasculogenetic models without increase of shear stress. In mouse air pouch (Supplemental Figure I , available online at http://atvb.ahajournals.org), PLC induced an increase of the vascular area compared to vehicle (PϽ0.05). In particular, PLC increased large-vessel recovery. Repeated PLC administration did not amplify the response (not shown). Representative pictures of chorioallantoic membrane ( Figure 3A , B) and quantification ( Figure 3C ) 3 days after PLC treatment (20 g/embryo) documented an increase of large vessels compared to control (PϽ0.05), comparable to that obtained with 50 ng/embryo fibroblast growth factor-2. Equimolar concentrations of L-carnitine and propionate were ineffective, indicating that PLC effects were not attributable to these moieties. In addition, evaluation of ␣-actin immunostaining of chorioallantoic membrane ( Figure 3D , E) revealed a marked increase of positive vessels in PLC compared to vehicle (Figure 3F; PϽ0.01). Finally, densitometric evaluation of reversetranscription polymerase chain reaction ( Figure 3G , H) demonstrated that PLC-induced vasculogenetic process was accompanied by a decrease of Nox4 and Nox2 transcripts compared to vehicle (PϽ0.01 and PϽ0.001, respectively).
PLC Reduces Vascular Endothelial Growth Factor and ICAM-1 and Increases iNOS Expression in Collateral Vessels
Immunohistochemical investigation ( Figure 4 ) showed that nonoperated hind limb collateral vessels were practically negative for vascular endothelial growth factor, iNOS, ICAM-1, and NF-Bp65 subunit; endothelial nitric oxide synthase immunostaining was faint. Seven days after injection, vascular endothelial growth factor-positive vessels and immunoreactivity were increased in treated groups compared to nonoperated hind limb but were less in PLC compared to controls (PϽ0.05 and PϽ0.01; Figure 4B ,C). The same was observed for ICAM-1 (PϽ0.01); however, iNOS increased (PϽ0.02). Although increased compared to nonoperated contralateral limbs, endothelial nitric oxide synthase, p65, and vascular cell adhesion molecule-1 expression did not vary in PLC compared to control groups. RAM11 ϩ macrophages around hind limb collateral vessels were almost absent in nonoperated rabbits. Seven days after injection, their number was slightly reduced in PLC (36.1Ϯ4.9/mm 2 ) compared to controls (45.2Ϯ6.6/mm 2 ; PϽ0.05). Reverse-transcription polymerase chain reaction showed a PLC-induced reduction of Nox4 and ICAM-1 transcripts in bioptic tissue 4 and 7 days after treatment (not shown).
PLC Exerts Opposite Effects on HUVEC and SMC Proliferation In Vitro
After 12 hours, PLC did not modify [ 3 H]thymidine-incorporated HUVEC and vascular SMC cultures (Supplemental Figure II) . At 24 hours, [ 3 H]thymidine incorporation was increased in HUVEC by PLC at 1 mmol/L (PϽ0.01) and was reduced at 2 mmol/L concentration (PϽ0.05) in SMC. After 48 hours, PLC also increased the HUVEC number (PϽ0.01) compared to untreated controls, with an IC50 of 1.43 mmol/L at 72 hours. The opposite was true for SMC (IC50 at 72 hours, 2.05 mmol/ L), with a slight reduction of cell viability at 1-and 2-mmol/L doses (91.0Ϯ1.2 and 89Ϯ2.0), partly because of increased apoptosis (4.3%Ϯ0.8% and 5.1%Ϯ1.0%, respectively) when compared to controls (1.1%Ϯ0.4%, PϽ0.05), according to previously reported data. 17 17 in HUVEC did not abolish PLC-induced ICAM-1 reduction ( Figure 5A ).
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PLC Increases iNOS Early and Downregulates Nox4 and ICAM-1 Levels in HUVEC
PLC Reduces ROS Accumulation and Downregulates Nox4, Nox2, and ICAM-1 Expression
In HUVEC, reverse-transcription polymerase chain reaction showed that Nox4 was more abundant than Nox2 transcripts, whereas Nox1 was barely expressed and Nox3 and Nox5 were absent ( Figure 5B ), confirming previously reported data. 18 Quantitative real-time polymerase chain reaction specified that the RNA copy number/g of Nox4 (15 540Ϯ1889) is much more than those of Nox2 (4.1Ϯ1.8), whereas remaining Nox isoforms were not quantifiable. As shown in Figure 5C , serum deprivation induced ROS accumulation in HUVEC (PϽ0.05). After 24 hours of treatment, PLC strongly reduced ROS level (PϽ0.05). Real-time polymerase chain reaction also documented that serum deprivation strongly increased Nox4 and ICAM-1 levels (PϽ0.001; Figure 5D , E). PLC at 1 mmol/L concentration strongly downregulated serum starvation-induced Nox4 after 4 hours and ICAM-1 transcripts after 12 hours (PϽ0.01). Western blotting confirmed the effect of PLC on Nox4 at protein level ( Figure 5F ). The successive 24-hour phorbol 12-myristate 13-acetate treatment induced Nox4 reexpression, abolished PLC effects, and restored ICAM-1 expression (PϽ0.05 and PϽ0.01, respectively; Figure 5G) . Similarly, we observed that serum deprivation slightly increased Nox2 transcript level (PϽ0.01), which was reduced by PLC after 4 hours (PϽ0.05; Figure 5H ). Remaining Nox isoforms were not modulated by PLC (data not shown).
PLC-Induced Reduction of ROS and ICAM-1 Is Nox4-Dependent
To check the contribution of Nox isoforms to PLCmediated ROS reduction in HUVEC, we used downregulation by siRNA. Nox4 siRNA inhibited serum deprivation-induced ROS and ICAM-1 increase and abolished PLC effects ( Figure 6A, B) . Instead, Nox2 downregulation by siRNA did not significantly modulate ROS production or PLC effects ( Figure 6C) , confirming that the PLC antioxidative effect is mainly Nox4-mediated. Moreover, Nox4 siRNA did not influence the Nox2 level; siNox2 did not influence Nox4 ( Figure 6D ) and ICAM-1 expression (not shown). Rac1 activity was not detected in HUVEC after serum deprivation and PLC treatment ( Figure 6E ). Finally, PLC-induced NF-B-related gene reduction in serum-deprived HUVEC occurred only after 12 hours ( Figure 6G-I) .
PLC Reduces Interaction Between Monocytes and HUVEC
An adhesion assay was performed to check the effects of PLC on the interaction between monocytes and HUVEC in vitro.
In control HUVEC, the number of adhering monocytes was extremely low. Serum deprivation induced an increase of monocyte adhesion that was partially inhibited by PLC (71.9%Ϯ2.7% of control).
Discussion
The first major finding of this study is that PLC ameliorated postischemic rabbit hind limb vascular perfusion and revascularization by accelerating flow recovery and vasodilative arteriogenetic remodeling in collateral vessels. PLC also increased vascularization in mouse air pouch and chorioallantoic membrane. PLC effects were dose-dependent and, when investigated, not observed using L-carnitine and propionate moieties. Adaptive dilatation and growth of preexisting collateral vessels play the most important role in tissue-saving and organ-saving processes after femoral artery occlusion or dissection. 13 The therapeutic ineffectiveness of capillary angiogenesis 19 leads researchers to further investigate arteriogenesis to discover new approaches to counteract adverse effects of vascular occlusion. 20 Arteriogenesis is a complex phenomenon with different phases. 21 Increased shear stress initiates arterial growth and induces marked endothelial activation of collateral vessels, with rapid adjustment of proximal preexisting tone. 22 Successively, structural remodeling by active parietal growth occurs. 12, 22 We documented an early greater blood flow recovery in PLC-treated samples compared to controls, in line with a positive effect on the early vasodilative adaptation phase. 23 In fact, blood flow recovery by PLC was significant after 4 days and preceded the vascular area increase on the seventh day. PLC-induced dilative adaptation confirms previous ex vivo experiments using subcutaneous arteries. 24 Moreover, PLC effects were found to be associated with increased endothelial cell proliferation but not SMC growth. These findings strongly suggest that endothelium is target for the pharmacological action of PLC. Healthy endothelium activation by various noxae upregulates vasoactive, inflammatory, and mitogenic factors. 21 Endothelial ROS accumulation plays a central role in vascular diseases, including atherosclerosis and restenosis. 3 Nox is the primary source of superoxide anions in the arterial wall. 21 In addition to structural (gp91 phox , p22 phox ) and regulatory components (p40 phox , p47 phox , p67 phox ), endothelial cells express Nox4 as a main active subunit. 18 Increased hemodynamic forces activate endothelial Nox. 25 We documented that PLC reduced ROS production, and this effect was mediated by downregulation of Nox4 activity in HUVEC. Endothelial machinery counteracting physiopathological changes by oxidative stress appropriately explains PLC-induced effects in patients with PAD. 26 Similar to other endothelial stress conditions, ROS generation triggers endothelial synthesis or release of inflammatory mediators and modulates downstream signaling pathways, including selectin ICAM-1. 27 In patients with PAD, elevated inflammatory biomarkers were found to be associated with impaired vascular function. 28 Postischemic ICAM-1 expression in PLC rabbit collateral 
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vessels was less than in controls, but it was still increased compared to sham-operated rabbits. This apparently contradicts ICAM-1-driven arteriogenesis, 29 because this selectin mediates leukocyte attachment or transmigration and favors the growth of collateral vessels. 22 Nevertheless, other substances, such as leptin, 30 have shown the capacity to stimulate arteriogenetic remodeling in the absence of a significant inflammatory macrophage-driven arterial growth. The early beneficial effect of PLC on blood flow recovery, despite the relatively lower Nox4-mediated increase of ICAM-1, are in line with a mechanotransduction mechanism leading to the direct activation of protective biophysical, biochemical, and gene regulatory responses in endothelial cells. 21 Excessive oxidative stress by ROS generation impairs endothelium-derived nitric oxide bioactivity. 3 Nitric oxide is a potent vasodilator released by endothelial cells, and dilatation of preexisting vessels plays a major role in early adaptation favoring flow recovery. 31 In patients with PAD, nitric oxide bioavailability and flow-mediated dilatation appear re- duced. 10 The increased iNOS activity we documented with PLC likely increases vascular nitric oxide availability in the postischemic acute phase, counteracting inactivation by ROS, 3 with the latter also reduced. Although referred as detrimental in atherosclerosis, 27 iNOS expression may be protective, as reported for allograft arteriosclerosis. 32 Altogether, our data provide further evidence of an alternative pathway for the early increase of postischemic collateral flow 30 and explain the clinical advantage with PLC in PAD patients. 10, 33 Although reported as a NF-B-regulated gene, 34 PLCinduced ICAM-1 downregulation preceded that of p65, suggesting NF-B-independent regulation, as for human aortic endothelial cells with other substances. 28 Reduction of endothelial ICAM-1 through the suppression of Nox4 activity is reported with other drugs, such as peroxisome proliferatoractivated receptor-␥ agonists. 35 Nox4 siRNA downregulated ICAM-1 expression in HUVEC, whereas vascular cell adhesion molecule-1 did not vary. Pretreatment with Nox inhibitor prevents ICAM-1 but not tumor necrosis factor-␣-induced NF-Bdriven vascular cell adhesion molecule-1 activation, 36 in line with the different regulatory pathway of selectins we documented.
At present, medical therapeutic opportunities of PAD still present more advantages and better safety compared to recently described methods, including therapeutic angiogenesis by stem cells. 37 Although trials documented that PLC improves walking capacity in severe PAD, its use is still unapproved in the United States. Hiatt 1, 38 associated the pharmacological activity of PLC with its property of providing further substrates for energy expenditure in ischemic tissues, particularly by improving muscle performance through a positive inotropic effect on mitochondria. Nevertheless, PLC reduces cell stress occurring during passage through the capillaries 39 and exerts vasculoprotective effects. 9, 40 Our results strongly support that PLC-induced clinical improvement in PAD patients derives from improved flow by stimulation of dilative adaptation of collateral vessels and the improvement of endothelial function. The latter is impaired in atherosclerotic plaques 41 and is associated with PAD, 4 in which a high risk of myocardial infarction, stroke, and vascular death is also observed. 2, 41 Although additional studies are needed, the impairment of endothelial function with PLC suggests new therapeutic perspectives in patients with concomitant coronary and PAD. 42 
Conclusion
Although well-detailed, the present study has some limitations. The major limitation is that 3-month-old rabbit hind limb acute ischemia is not fully representative of abnormalities observed in patients with PAD, in whom atherosclerotic occlusion of leg arteries is chronically established. 1 These patients generally display advanced age and risk factors that cause atherosclerotic progression and adverse clinical outcomes. 1 Altered lipid metabolism and aging influence endothelial proliferation and motility; 43 moreover, arteriogenetic adaptation is impaired in hypercholesterolemic mice. 44 Nevertheless, our results align well with the reduction of impaired endothelial function observed in PAD patients receiving PLC. 10 Data concerning pharmacokinetics of PLC suggest a rapid plasmatic clearance but a slow but progressive accumulation of radioactivity in heart and striated muscle, with a progressive increase of tissue-to-plasma ratio, consistent with the therapeutic efficacy of PLC. 45 Of course, the effects of a single-dose intramuscular injection cannot be representative of chronic therapy; nevertheless, our finding helps clarify the beneficial effects of PLC. 7 The lowering of atherosclerotic risk factors remains a goal of medical PAD treatment. 2 PLC administration reduces aortic and coronary atherosclerosis and plasma triglycerides in hyperlipemic aged rabbits. 46 Our data cannot exclude that improvement of postischemic hind limb vascularization derives also from PLC-induced changes in shear stress; nevertheless, the similarity of findings in the different vasculogenetic models shows support against this possibility. Finally, further studies are needed to investigate PLC effects in regions on femoral artery occlusion, where profound ischemia prevails and capillary proliferation and tissue repair occur. 47 In conclusion, our results indicate that PLC accelerates blood flow recovery and the restoration of vascular function by sustaining a positive dilative arteriogenetic remodeling and by reducing oxidative stress-induced impaired endothelial function. The latter involves mainly Nox4 activity and downstream pathways, including ICAM-1 and iNOS expression. The present findings better-address PLC as a therapeutic strategy aimed at counteracting manifestations of PAD and suggest additional pharmacological studies targeting impaired endothelial function occurring during cardiovascular diseases.
